Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

J Pediatric Infect Dis Soc 2019 Mar 8. Epub 2019 Mar 8.

GlaxoSmithKline, Rockville, Maryland.

Background: MMR II (M-M-R II [Merck & Co, Inc.]) is currently the only measles, mumps, and rubella (MMR) vaccine licensed in the United States. A second MMR vaccine would mitigate the potential risk of vaccine supply shortage or delay. In this study, we assessed the immunogenicity and safety of another MMR vaccine (MMR-RIT [Priorix, GlaxoSmithKline]) compared with those of the MMR II in 12- to 15-month-old children who received it as a first dose.

Methods: In this phase III, observer-blinded, noninferiority, lot-to-lot consistency clinical trial (ClinicalTrials.gov identifier NCT01702428), 5003 healthy children were randomly assigned to receive 1 dose of MMR-RIT (1 of 3 production lots) or MMR II along with other age-recommended routine vaccines. We evaluated the immunogenicity of all vaccines in terms of antibody concentrations (by using an enzyme-linked immunosorbent assay or electrochemiluminescence assay) and/or seroresponse rates 43 days after vaccination. We also assessed the reactogenicity and safety of the vaccines.

Results: Immunoresponses after vaccination with MMR-RIT were robust and noninferior to those after vaccination with the MMR II. Immunogenicity of the 3 production lots of MMR-RIT was consistent; more than 97% of the children had a seroresponse to MMR components. The coadministered vaccines elicited similar immunoresponses in the MMR-RIT and MMR II groups. Both MMR vaccines resulted in comparable reactogenicity profiles, and no safety concerns were detected.

Conclusions: If licensed, the MMR-RIT could provide a valid option for the prevention of measles, mumps, and rubella in children in the United States and would reduce potential risks of a vaccine shortage.

Download full-text PDF

Source
https://academic.oup.com/jpids/advance-article/doi/10.1093/j
Publisher Site
http://dx.doi.org/10.1093/jpids/piz010DOI Listing
March 2019
15 Reads

Publication Analysis

Top Keywords

mmr vaccine
12
mmr
10
lot-to-lot consistency
8
measles mumps
8
noninferiority lot-to-lot
8
phase iii
8
production lots
8
mumps rubella
8
united states
8
immunogenicity safety
8
mmr-rit
6
vaccine
6
children
5
assay electrochemiluminescence
4
electrochemiluminescence assay
4
immunosorbent assay
4
enzyme-linked immunosorbent
4
antibody concentrations
4
concentrations enzyme-linked
4
terms antibody
4

Altmetric Statistics

104 Tweets

Similar Publications